Tscan Therapeutics is trading at $0.19, down 5.93%, with no clear company-specific explanation identified for the October 29 decline.
- The latest reported company news was an October 28 collaboration concerning automated manufacturing of TSC-101; it was not reported as the cause of the decline.
- Broader markets were weak, with the Nasdaq reported down 1.52%, but available evidence does not establish a direct link to the stock’s move. Confidence is low.